Emma Ogburn
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, Health Systems, Economic Evaluations, Quality of Life, Blood Pressure and Hypertension Studies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research
Most-Cited Works
- → Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial(2018)407 cited
- → Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial(2022)395 cited
- → Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)307 cited
- → Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)303 cited
- → Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial(2021)233 cited
- → Prevalence of chronic kidney disease in the community using data from OxRen: a UK population-based cohort study(2020)79 cited
- → Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)77 cited
- → Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial(2023)77 cited
- → Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial(2022)51 cited
- → Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care(2018)49 cited